Search Results

Nucleus RadioPharma today announced the closing of a Series A extension round with new investor AstraZeneca (LSE/STO/Nasdaq: AZN).

Nucleus Genomics announced the launch of its DNA analysis product to bring the benefits of personalized medicine to everyone.

n a joint effort to provide lower cost and more defined reagents and media to the cell and gene therapy market, Nucleus Biologics, The Cell Performance Company™, a leading provider of custom cell culture media solutions for the cell and gene therapy industry, has signed a manufacturing, distribution, and collaboration agreement with Core Biogenesis, an innovator in the field of recombinant human proteins expressed in plants.

ARTBIO, Inc. and Nucleus RadioPharma Inc. announced a strategic manufacturing and supply agreement to support ARTBIO’s therapeutic product manufacturing.

Eckert & Ziegler and Nucleus RadioPharma signed extensive supply agreements for major therapeutic radioisotopes.

Nucleus RadioPharma, the world’s first fully integrated development, manufacturing, and supply chain organization for radiopharmaceuticals, today announced the appointment of Chris McDonald, Global Head of Technical Operations at Kite, a Gilead Company, to its Board of Directors.

SHINE Technologies today announced a long-term supply agreement with Nucleus RadioPharma, the world’s first fully integrated development, manufacturing, and supply chain organization for radiopharmaceuticals.

Nucleus RadioPharma, the world’s first fully integrated development, manufacturing, and supply chain organization for radiopharmaceuticals, announced the expansion of its executive leadership team with Mark Przekop joining as Chief Operating Officer.

Biologics Market Outlook 2024-2032:

Nucleus RadioPharma, the world’s first fully integrated development, manufacturing, and supply chain organization for radiopharmaceuticals, announced the appointment of Kathy Spencer-Pike as Chief Commercial Officer.